Unique ID issued by UMIN | UMIN000041013 |
---|---|
Receipt number | R000046828 |
Scientific Title | A Study on the Effect of Food Containing Plant Extract on Postprandial GLP-1 -A Randomized, Double-blind, Placebo-controlled, Cross-over Study- |
Date of disclosure of the study information | 2020/07/08 |
Last modified on | 2021/10/26 14:22:53 |
A Study on the Effect of Food Containing Plant Extract on Postprandial GLP-1
-A Randomized, Double-blind, Placebo-controlled, Cross-over Study-
A Study on the Effect of Food Containing Plant Extract on Postprandial GLP-1
A Study on the Effect of Food Containing Plant Extract on Postprandial GLP-1
-A Randomized, Double-blind, Placebo-controlled, Cross-over Study-
A Study on the Effect of Food Containing Plant Extract on Postprandial GLP-1
Japan |
No
Adult |
Others
NO
To comfirm the effect of food containing plant extract on Postprandial GLP-1
Efficacy
GLP-1
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
Food containing plant extract, single ingestion. Wash out. Food not containing plant extract, single ingestion.
Food not containing plant extract, single ingestion. Wash out. Food containing plant extract, single ingestion.
20 | years-old | <= |
65 | years-old | > |
Male and Female
(1)Healthy males and females aged 20 to 64 years-old.
(2)Subjects who do not habitually consume a large amounts of alcohol.
(3)Subjects who are judged not suffering from a disease by the investigator.
(4)Subjects who can make self-judgment and are voluntarily giving written informed consent.
(1)Subjects who have a chronic disease and regularly use medications.
(2)Subjects who can't stop using supplements and/or functional foods (including Food for Specified Health Uses or Foods with Function Claims) during test periods.
(3) Subjects who can't stop drinking from 2 days before each measurement.
(4)Subjects who have declared allergic reaction to ingredients contained in test foods or loading foods.
(5) Subjects who contract or are under treatment for diseases (e.g., diabetes, liver disease, kidney disease, heart disease, respiratory disease, endocrine disease and/or metabolic disease).
(6)Subjects who have a history and/or a surgical history of digestive disease affecting digestion and absorption.
(7)Subjects who are judged unsuitable for the current study by the screening tests.
(8)Subjects who are diagnosed as anemic by the screening tests and unsuitable for frequent blood sampling.
(9) Subjects who have had diarrhea within the last one week prior to the screening tests.
(10)Subjects who have donated over 200 mL of blood and/or blood components within the last one month or over 400 mL of blood and/or blood components within the last three months prior to the current study.
(11)Subjects who are under treatment for or have a history of drug addiction and/or alcoholism.
(12) Subjects who are shiftworker and/or midnight-shift worker.
(13) Subjects who are planning to participate in other clinical studies during test periods and/or had participated in other clinical studies within the last one month prior to the current study.
(14) Subjects who are planning to become pregnant after informed consent, pregnant or lactating.
(15) Subjects who are judged unsuitable for the current study by the investigator for other reasons.
12
1st name | Masahiko |
Middle name | |
Last name | Tokushima |
Maebashi North Hospital
Director
371-0054
692 Shimohosoi-machi,Maebashi-shi,Gumma
027-235-3333
sagawa@mc-connect.co.jp
1st name | Yoshika |
Middle name | |
Last name | Komori |
KSO Corporation
Sales department
105-0023
1-9-7 Shibaura, Minato-ku, Tokyo
03-3452-7733
yoshi@kso.co.jp
KSO Corporation
TOYO SHINYAKU Co., Ltd.
Profit organization
Ethical Committee of Kobuna Orthopedics Clinic
5-656-17 Joto-machi, Maebashi-shi, Gumma
027-212-5608
sagawa@mc-connect.co.jp
NO
2020 | Year | 07 | Month | 08 | Day |
https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000046828
Published
http://www.pieronline.jp/content/article/0386-3603/49020/321
12
Statistically significant difference was confirmed in the primary outcome.
2021 | Year | 10 | Month | 26 | Day |
Males and females aged 20 to 64 years old.
Enrolled(n=12)
Completed(n=11)
Analysed(n=7)
No adverse events were observed that be related to test food.
GLP-1
Main results already published
2020 | Year | 06 | Month | 24 | Day |
2020 | Year | 07 | Month | 02 | Day |
2020 | Year | 07 | Month | 09 | Day |
2020 | Year | 08 | Month | 15 | Day |
2020 | Year | 07 | Month | 06 | Day |
2021 | Year | 10 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046828
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |